Appropriate Use of Precision Oncology

Data and Guidance for a New Treatment Paradigm

ClinicalPath

Challenge

Precision oncology is a rapidly developing field that uses appropriate biomarker and mutation testing practices to enable oncologists to select the optimal targeted therapy to improve patient outcomes. Appropriate testing is also required for reimbursement of both testing analysis and the targeted therapy.

This can be quite difficult, however, as:

- the literature on actionable biomarkers and genetic variants changes frequently, as does the approved indication for targeted therapies, resulting in a high level of variation in biomarker testing and appropriate utilization of targeted therapies.
- newly published biomarkers often are under-tested.

Using Non-Small Cell Lung Cancer (NSCLC) as an example, optimized use of precision oncology is currently hindered by:

- **Frequent field advances** – As the number of molecular biomarkers and targeted therapies for NSCLC grow, so do the associated companion and complementary tests, resulting in unwarranted variation in clinical practice.
- **Inappropriate testing** – An analysis of real-world patterns of EGFR testing and treatment based on a random sample of patients with NSCLC found that less than 25% of stage IV, adenocarcinoma patients received EGFR testing.[i]
- **Inappropriate use of targeted therapies** – A recent study found that only 11.3% of NSCLC patients were tested for PD-L1 expression before receiving either nivolumab or pembrolizumab.[ii]

Opportunity

With the growth of targeted therapies in clinical practice, appropriate biomarker testing will become increasingly important for patient outcomes and reimbursement approval. Your institution can be ready – and ahead of the curve – if you put in place the tools needed to overcome barriers and expedite success in this new field.

When ClinicalPath (formerly Via Oncology) pathways were modified to capture NSCLC biomarker test results, appropriate targeted agents were selected for **91.9%** and **86.5%** of patients who were ALK translocation positive and EGFR sensitizing mutation positive, respectively.[iii]

For breast cancer patients who had ER-positive, HER2Neu-negative disease with zero to three positive nodes, **92.7%** had diagnostic testing for the use of adjuvant chemotherapy. Where chemotherapy followed by hormone therapy was indicated, pathway adherence was **96.6%**.[iv]

## How Elsevier's ClinicalPath Can Help Your Institution

For your providers:

- Identifies the **appropriate biomarkers** to be tested, specific to the patient presentation, ensuring your biomarker testing is standardized, evidence-based and in line with leading practices.
- Where a test's results have not yet been received, providers can **"pause" the pathway**, allowing them to pick up at the relevant step when the results are in.
- Based on the biomarker testing results, the pathway identifies the **optimal treatment regimen**, ensuring the appropriate use of targeted therapies.

For your patients:

- **Improve patient outcomes** by ensuring the right targeted therapies are used appropriately.
- Incorporate **information for patients** – including treatment consent forms, treatment plans that outline disease staging and biomarker results, drug-specific patient education and patient assistance forms for subsidized drug access – ensuring they are informed about their cancer and contributing to **treatment compliance**.

For your institution:

- Provides **detailed analytics** on biomarker testing rates, assay results and on- and off-pathway use of targeted therapies, supporting your leadership team in reporting requirements for quality programs and reimbursement approvals.
- Your leadership team can use this information to **standardize precision oncology practices** across sites, aligned to the **latest evidence**.

Resources

i   Real-World Patterns of EGFR Testing and Treatment with Erlotinib for Non-Small Cell Lung Cancer in the United States, PLoS One, June 13, 2016, https://www.ncbi.nlm.nih.gov/pubmed/27294665

ii   Rates of PD-L1 expression testing in U.S. community-based oncology practices (USCPs) for patients with metastatic non-small cell lung cancer (mNSCLC) receiving nivolumab (N) or pembrolizumab (P), Journal of Clinical Oncology, published online May 30, 2017, https://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.11596

iii   Actionable biomarkers in a non-small cell lung cancer (NSCLC) clinical pathway (CP), Journal of Clinical Oncology, presented February 26, 2016, https://meetinglibrary.asco.org/record/121367/abstract

iv   Pathways Clinical Decision Support for Appropriate Use of Key Biomarkers, Journal of Oncology Practice, June, 2016, https://www.ncbi.nlm.nih.gov/pubmed/27221995

To learn more, visit Elsevier.com/clinicalpath

ELSEVIER

ClinicalPath